Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
https://zakmir.com/stock-market-watch-val-ufo-wsbn/#gs.ejueu2
hTtps://www.valirx.com/wp-content/uploads/2020/08/Valirx-Plc-August-2020-Answers.pdf
antfolli looks like you want a lower entry? why do you constantly come on and talk bs when you have no interest in this share? im sure the Japanese know something you dont for them to have an interest in VAL. Please give it a rest!
I agree Mr nation also if val201 wasnt as good then why would they use val201 as a potential cure for covid-19 also I agree there are too many trolls on this bb. Best to ignore them. Best to hold for gold. Good luck all
Mathsfrop for u it may not...but for me it says alot of things. Each to their own. Tgey have spent such a long time to get this far. If it was not worthwhile it would have been stopped a long time ago. So far we know its well tolerated and safe. The rest we shall find out soon. You have to be in it to win it...gla
The Phase 1/2 clinical trial of VAL201 in the treatment of men with prostate cancer was closed to further recruitment on 27 January 2020, with recruitment standing at a total of 12 patients dosed across 5 cohorts. The dose escalation was carried out from 0.5 mg/kg up to 8 mg/kg with dosing being carried out once a week.
The trial considered the safety and tolerability of drug administration, alongside pharmacokinetics and disease impact. Although the COVID-19 pandemic lockdown initially cast concern on the time schedules for data verification processes, the project remains on track to release headline results within Q3 2020, which will provide basic details of safety, tolerability and disease impact. More detailed observations on the pharmacokinetics and complete summaries of patient demographics, biochemistry and study conduct will be available when the Clinical Study Report is completed in Q4 2020